Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Corporate Update (July 2025)
25 slides from Krystal Biotech's corporate update, Jul 24, 2025
Slide 1: KB304 PEARL-2 Results for Dynamic Wrinkles of the Décolleté
July 2025 1 KB304 PEARL-2 Results for Dynamic Wrinkles of the Décolleté r e p l e n i s h r e s t o r e Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 This presentation and the accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal B
Slide 3: Jeune Team / Today's Presenters and Participants
3 Jeune Team Name Title / Years of Experience Prior Experience Marc Forth Chief Executive Officer 30 years • President & CEO, AEON Biopharma • In-licensed lead asset from Daewoong • Led separation from Alphaeon and merger with SPAC to take AEON public • Board Member Jeune • 16 years at Allergan • SV
Slide 4: Jeune Aesthetics: A Wholly Owned Subsidiary of Krystal Biotech, Inc.
Jeune Aesthetics: A Wholly Owned Subsidiary of Krystal Biotech, Inc. 4 *Jeune holds exclusive license to Krystal’s HSV-1 gene delivery platform for cash pay markets Subsidiary Dedicated to Cash Pay Markets* Clinical Development Commercial Fully integrated biotech developing portfolio of genetic
Slide 5: KB304 Designed to Increase Type III Collagen and Elastin Levels in Aging Skin
KB304 Designed to Increase Type III Collagen and Elastin Levels in Aging Skin 5 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. KB304 Payloads Type I Collagen Type III Collagen Type IV Collagen Elastin Percentage in the skin 70-80% 15%-20% Small % 2-3% Function Forms dense, tightly pack
Slide 6: * = = —L4 = } x po <\'* tw S—7) & eat
* 3 = = —L4 = } x po 7 2 <\'* tw S—7) & 4 eat = ~ a a <2 >. _ re ~~ a = i 4 an e —— » =e “4 if . A ig Seay »\ a \' JEUNE 6 y " ~~
Slide 7: PEARL-2 Evaluating KB304 in Dynamic Wrinkles of the Décolleté
7 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. PEARL-2 Evaluating KB304 in Dynamic Wrinkles of the Décolleté Study Objective and Design • Randomized (2:1), double-blind, placebo-controlled study evaluating KB304 for the improvement of dynamic wrinkles of the décolleté in adults • Key
Slide 8: Safety Findings in the Décolleté Region
Safety Findings in the Décolleté Region • All AEs were mild or moderate in severity and transient in nature. No serious AEs or SAEs were observed in the study • The most common AEs were pruritis, myalgia, and skin reaction • Both the frequency and duration of AEs decreased with subsequent doses © Co
Slide 9: KB304 Showed a Clear Separation from Placebo
9 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. KB304 Showed a Clear Separation from Placebo Follow Up Period After Treatment KB304 (n = 11) Placebo (n = 7) 0% 20% 40% 60% 80% 100% One Month Two Months Three Months One Month Two Months Three Months Investigator GAIS Assessed Lines / W
Slide 10: Improvements Across Multiple Other Skin Attributes (Investigator)
10 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. Improvements Across Multiple Other Skin Attributes *Defined as GAIS scores of +1 or +2 Investigator Assessed Skin Attributes Follow Up Period After Treatment One Month Two Months Three Months 0% 20% 40% 60% 80% 100% One Month Two Months
Slide 11: Improvements Across Multiple Other Skin Attributes (Subject)
11 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. Improvements Across Multiple Other Skin Attributes *Defined as GAIS scores of +1 or +2 Subject Assessed Skin Attributes Follow Up Period After Treatment KB304 (n = 10-11) Placebo (n = 7) 0% 20% 40% 60% 80% 100% One Month Two Months Thre
Slide 12: KB304 Subject Satisfaction Increased with Time
12 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. KB304 Subject Satisfaction with Line / Wrinkle Improvement Increased with Time KB304 (n = 11) Placebo (n = 7) One Month Two Months Three Months
Slide 13: Décolleté Before and After Images
Décolleté Before and After Images 13 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. Baseline Three Month Follow Up
Slide 14: Décolleté Before and After Images
Décolleté Before and After Images 14 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. Baseline Three Month Follow Up
Slide 15: Next Steps and Market Opportunity
Next Steps and Market Opportunity 15
Slide 16: Next Steps for KB304
Next Steps for KB304 16 © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. Select indication for Phase 2 development – completed, décolleté selected Develop décolleté-specific photonumeric scale (Jeune Décolleté Wrinkle Scale) and assessment tool for patient report outcomes – completed
Slide 17: Jeune is Focused on Addressing the Underlying Cause of Skin Aging
17 Damage FillParalyze Replenish & Restore Using light and sound waves, energy-based devices damage the skin with the hope of triggering a wound healing response Whether hyaluronic acid, bovine collagen, or others, fillers add artificial volume to temporarily decrease the appearance of wrinkles By i
Slide 18: Ideal Primary Tool for Skin Rejuvenation
Address Root Cause of Skin Aging Injected with Standard Syringes and Needles Shipped and Stored like other Injectables No Capital Equipment Investment Jeune Technology Jeune Technology Jeune Technology Jeune Technology © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. 18 Ideal Primary Too
Slide 19: Significant Existing Consumer Demand
9.9M Cosmetic Neurotoxin Injections and 6.3M Cosmetic Filler Injections in US1 No FDA Approved Aesthetic Injectables for the Décolleté © Copyright 2025 Jeune Aesthetics, Inc. All rights reserved. 1 American Society of Plastic Surgeons Procedural Statistics Release 2024, excludes fillers for lip augm
Slide 20: Several Factors Driving Growth in Global Skin Rejuvenation Market
1. Br J Dermatol 2023; 189:i17–i23 2. United Nations, Department of Economic and Social Affairs, World Prospects 2024 3. Gen Z and Gen Alpha Infographic Update – McCrindle 4. Ozempic Is Changing People’s Skin, Say Plastic Surgeons | Allure 5. Realself Culture Report, 2023, Survey YouGov 20 Global Sk
Slide 21: Projected Aesthetic Treatment Ladder
OTC Beauty Lotions Aesthetic Practice Visit Reverse Skin Aging with Jeune Technology Addition of Neurotoxin and Filler 21 Treatment Goal Maintain youthful skin naturally; delay, avoid, or reduce toxins, fillers and EBD procedures Projected Aesthetic Treatment Ladder © Copyright 2025 Jeune Aesthetics
Slide 22: Robust Pipeline of Candidates Addressing Significant Market Opportunities
22 Program Indication Key Skin Protein Skin Quality Attribute Discovery Preclinical Phase 1 Phase II Phase III Marketed KB304 Dynamic Wrinkles of the Décolleté Type III collagen (COL3) + Elastin (ELN) Structure, Flexibility and Elasticity KB301 TBD COL3 Structure and Flexibility KB303 TBD ELN Skin E
Slide 23: Long Term Strategic Vision for Jeune
23 Long Term Strategic Vision for Jeune Vision: Creating a new category of minimally invasive therapies to fundamentally address the underlying biology of aging skin by replenishing native proteins and restoring the skin Jeune is well-positioned to rapidly advance KB304 through value-creating Phas
Slide 24: Key Highlights
24 Key Highlights De-Risked, Validated Approach that Directly Addresses the Root Causes of Aging Skin Leverages Krystal’s Validated Gene Delivery Platform, Comprehensive IP, Manufacturing Capabilities, Operational and Regulatory Expertise Experienced Management Team and Advisors with Significant Exp
Slide 25: Closing and Q&A
\ Closthg ant > Q&A JEUNE